Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.
| Website | https://amolytpharma.com |
| Employees | 19 (8 on RocketReach) |
| Founded | 2015 |
| Phone | +33 4 28 01 21 54 |
| Technologies |
JavaScript
,
HTML
,
PHP
+13 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Rare Disease Therapeutics, Endocrine Disorders, Innovative Medicines, Hormone Therapy, New Drug Development, Peptide Therapeutics, Pharmaceutical Research, Drug Discovery, Biopharmaceutical, Clinical Development, Bone Health, Drug Delivery, Clinical Trials, Patient Centric |
| Competitors | AstraZeneca, Lilly India, Novartis, Sanofi, Bristol Myers Squibb, Pfizer, Novo Nordisk, Merck & Co., Inc., Amgen, AbbVie +41 more (view full list) |
Looking for a particular Amolyt Pharma employee's phone or email?
Amolyt Pharma Questions
Michael Culler is the Chief Scientific Officer of Amolyt Pharma.
8 people are employed at Amolyt Pharma.
Top Amolyt Pharma Employees
-
Michael Culler
Chief Scientific Officer at Amolyt Pharma
Boston, MA, US5+ -
Laetitia Ouafki
Director of Quality Assurance at Amolyt Pharma
Caluire-et-Cuire, FR1 -
1
-
Nadège L.
Clinical Project Leader at Amolyt Pharma
Île-de-France, France
